{"public_id":"cl_73803dd6df5d3c5fd88f9269bb5624a2","status":"active","superseded_by_public_id":null,"corpus_id":84844238,"text":"Combining lesion-wide predictions on a patient level, immunotherapy response could be predicted with an AUC of up to 0.76 for both cancer types (P < 0.001), resulting in a 1-year survival difference of 24% (P = 0.02).","confidence":0.95,"paper":{"corpus_id":84844238,"title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","url":"https://sah.borca.ai/papers/84844238"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":2},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_05b37084c32d0aa28947d25f887b1022","name":"patient-level prediction","description":"Combining lesion-wide predictions to predict immunotherapy response at the patient level.","types":["method","prediction approach"],"url":"https://sah.borca.ai/concepts/co_05b37084c32d0aa28947d25f887b1022"},{"public_id":"co_955040ae408255277546c9e5d17a810d","name":"immunotherapy response","description":"The outcome of whether a patient responds to anti-PD1 therapy, used as the prediction target.","types":["outcome","phenotype"],"url":"https://sah.borca.ai/concepts/co_955040ae408255277546c9e5d17a810d"},{"public_id":"co_e2eec5950c4d38658a7df003f32be5da","name":"1-year survival difference","description":"A 24% difference in 1-year survival observed between predicted responder and nonresponder groups.","types":["measurement","outcome"],"url":"https://sah.borca.ai/concepts/co_e2eec5950c4d38658a7df003f32be5da"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_73803dd6df5d3c5fd88f9269bb5624a2"}